Diane E T Bastiaans1, Silvia Forcat, Hermione Lyall, Tim R Cressey, Rawiwan Hansudewechakul, Suparat Kanjanavanit, Antoni Noguera-Julian, Christoph Königs, Jamie R J Inshaw, Suwalai Chalermpantmetagul, Yacine Saïdi, Alexandra Compagnucci, Lynda M Harper, Carlo Giaquinto, Angela P H Colbers, David M Burger. 1. From the *Department of Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; †MRC, Clinical Trials Unit, London, United Kingdom; ‡Imperial College Healthcare NHS Trust, Department of Pediatrics, St Mary's Hospital, London, United Kingdom; §Program for HIV Prevention and Treatment/IRD UMI-174, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand; ¶Department of Pediatrics, Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand; ‖Department of Pediatrics, Nakornping Hospital, Chiang Mai, Thailand; **Unitat d´Infectologia, Servei de Pediatria, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain; ††Department of Pediatrics and Adolescent Medicine, J.W. Goethe University, Frankfurt, Germany; ‡‡INSERM, SC10-US19, Villejuif, France; and §§Department of Pediatrics, University of Padova, Italy.
Abstract
BACKGROUND: Lopinavir/ritonavir (LPV/r) pediatric tablets (100/25 mg) are approved by the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) as part of combination antiretroviral therapy. Dosing is based on body weight bands or body surface area under FDA approval and only body surface area by the EMA. This can lead to a different recommended dose. In addition, weight band-based dosing has not been formally studied in the target population. We evaluated the pharmacokinetics (PK) of LPV/r in children, administered twice daily according to the FDA weight bands, using pediatric tablets. METHODS: Fifty-three HIV-infected children were included in the PK substudy of the Paediatric European Network for the Treatment of AIDS 18 trial (KONCERT). In this study, children were randomized to receive LPV/r twice or once daily, according to FDA weight bands. A PK assessment was performed in 17, 16 and 20 children in the 15-25 kg, ≥ 25-35 kg and >35 kg weight band, respectively, while children took the tablets twice daily. Rich sampling was performed, and PK parameters were calculated by noncompartmental analysis. Given the high percentage of Asian children, it was also tested whether there was a difference in PK parameters between Asian and non-Asian children. RESULTS: For the total group, LPV geometric mean AUC0-12, Cmax and C12 were 106.9 h × mg/L, 12.0 mg/L and 4.9 mg/L, respectively. There were no significant differences in LPV PK parameters between the weight bands. In addition, weight was not found to be associated with variability in Cmax, C12 or AUC0-12 for the LPV PK parameters. CONCLUSIONS: FDA weight band-based dosing recommendations provide adequate exposure to LPV when using LPV/r pediatric tablets.
BACKGROUND: Lopinavir/ritonavir (LPV/r) pediatric tablets (100/25 mg) are approved by the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) as part of combination antiretroviral therapy. Dosing is based on body weight bands or body surface area under FDA approval and only body surface area by the EMA. This can lead to a different recommended dose. In addition, weight band-based dosing has not been formally studied in the target population. We evaluated the pharmacokinetics (PK) of LPV/r in children, administered twice daily according to the FDA weight bands, using pediatric tablets. METHODS: Fifty-three HIV-infected children were included in the PK substudy of the Paediatric European Network for the Treatment of AIDS 18 trial (KONCERT). In this study, children were randomized to receive LPV/r twice or once daily, according to FDA weight bands. A PK assessment was performed in 17, 16 and 20 children in the 15-25 kg, ≥ 25-35 kg and >35 kg weight band, respectively, while children took the tablets twice daily. Rich sampling was performed, and PK parameters were calculated by noncompartmental analysis. Given the high percentage of Asian children, it was also tested whether there was a difference in PK parameters between Asian and non-Asian children. RESULTS: For the total group, LPV geometric mean AUC0-12, Cmax and C12 were 106.9 h × mg/L, 12.0 mg/L and 4.9 mg/L, respectively. There were no significant differences in LPV PK parameters between the weight bands. In addition, weight was not found to be associated with variability in Cmax, C12 or AUC0-12 for the LPV PK parameters. CONCLUSIONS: FDA weight band-based dosing recommendations provide adequate exposure to LPV when using LPV/r pediatric tablets.
Authors: Jincheng Yang; Mina Nikanjam; Brookie M Best; Jorge Pinto; Ellen G Chadwick; Eric S Daar; Peter L Havens; Natella Rakhmanina; Edmund V Capparelli Journal: J Clin Pharmacol Date: 2018-09-25 Impact factor: 3.126
Authors: Hylke Waalewijn; Anna Turkova; Natella Rakhmanina; Tim R Cressey; Martina Penazzato; Angela Colbers; David M Burger Journal: Ther Drug Monit Date: 2019-08 Impact factor: 3.681